Biography:Aron Mosnaim
Aron David Mosnaim | |
---|---|
Occupation | Neuroscientist, researcher, and academic |
Academic background | |
Education | PharmD degree PhD in Organic Chemistry |
Alma mater | University of Chile University of Strathclyde |
Academic work | |
Institutions | Rosalind Franklin University of Medicine and Science International Neuropsychiatry Consultants |
Aron David Mosnaim is a neuroscientist, researcher, and academic. He is a professor of Cellular and Molecular Pharmacology and an adjunct professor of Psychiatry and Behavioral Sciences in the Chicago Medical School at Rosalind Franklin University of Medicine and Science.[1]
Mosnaim is most known for his research covering the areas of basic and clinical neuro- and immunopharmacology of biogenic amines and opioid peptides in neuropsychiatric conditions, including depression, headache pain, as well as movement and posttraumatic stress disorders.[2] He has co-edited four scientific books on Noncatecholic Phenylethylamines (2 volumes),[3] Posttraumatic Stress Disorder,[4] and Tardive Dyskinesia.[5]
Mosnaim has served as a Consultant to the Pan American Health Organization (1982–1985), Member of the United States Pharmacopeia Convention (1990 and 1995), and Director of International Neuropsychiatry Consultants (1987–2020). Additionally, he is a Fellow of The Chemical Society (1977) and a Senior Fellow of the American Institute of Therapeutics (2019).[1]
Early life and education
Mosnaim earned a Doctor of Pharmaceutical Sciences degree from the University of Chile (1964) and joined the Faculty of the university's School of Medicine. He was awarded a PhD degree in Organic Chemistry from Glasgow’s Strathclyde University (1969). After a brief tenure at the University of Chicago, he received a postdoctoral fellowship at Northwestern University (1970).[2]
Career
In 1971, Mosnaim joined the University of Health Sciences/The Chicago Medical School as an assistant professor in the Department of Pharmacology. He was promoted to Associate Professor and Acting Chairman (1974), and to a Full Professorship in 1979. He has been serving as a professor of Cellular and Molecular Pharmacology and adjunct professor of Psychiatry and Behavioral Sciences at The Chicago Medical School/Rosalind Franklin University.[1]
Mosnaim holds an Honorary Full Professorship at the University of Chile College of Pharmaceutical Sciences.
Research
Mosnaim has published over 150 papers in peer-reviewed Journals, more than 20 invited reviews and book chapters, and presented research in more than 200 scientific meetings.[2]
Early in his research career (1967), Mosnaim contributed to elucidate the metabolic pathway of the then widely used toxic insecticide DDT (dichlorodiphenyltrichloroethane), and in a series of publications (1969–1972) helped to understand the mechanism of halogenation by cupric salts of carcinogenic anthracene and pyrene compounds.[6] His laboratory demonstrated the presence of phenylethylamine, commonly viewed as the endogenous amphetamine, in mammalian tissues, and his work elucidated this amine’s in vivo and in vitro brain metabolic pathway.[7][8][9] His work, animal models, contributed to establish phenylethylamine brain levels as a biological marker for various neuropsychiatric disorders, and to evaluate its brain changes in response to different classes of psychotropic drugs.[10][11] Further research identified some of the physiological functions, and described relevant behavior and toxicological effects of phenylethylamine and various structurally related trace amines.[12][13]
Mosnaim reported plasma levels of the endogenous opioid pentapeptide methionine-enkephalin in various patient populations, and the effect of selected classes of drugs on its degradation kinetics,[14] suggesting that its significant increase in chronic cluster and migraine patients during an acute headache episode could serve as a biological marker for these illnesses.[15][16] He also clarified reports of the activity of platelet monoamine oxidase and the role of dietary phenylethylamine and tyramine in the etiology of migraine headaches.[17]
Mosnaim contributed to document the association of tardive dyskinesia and drug-induced parkinsonism, and in identifying sub-types, cognitive deficits, and some of the risk factors associated with increased vulnerability to this condition.[18][19][20][21] He participated in studies finding comorbidity of pain, dermatological and allergic conditions, as well as decreased natural killer cell activity, in posttraumatic stress disorder patients.[22] He reported the decrease of this immune function in septic shock and human immunodeficiency virus-1 positive individuals, as well as its significant increase by various substances with widely different chemical structures and biological activities, e.g., enkephalins, α-interferon, interleukin-2, taxol, and lipopolysaccharide.[23][24][25]
Bibliography
Selected edited books
- Noncatecholic phenylethylamines Part 1 (1978) ISBN 0-8247-6616-4
- Noncatecholic phenylethylamines Part 2 (1980) ISBN 0-8247-6721-7
- Tardive Dyskinesia: Biological Mechanisms & Clinical Aspects (1989) ISBN O-8804-8176-5
- Posttraumatic Stress Disorder: Etiology, Phenomenology, and Treatment (1990) ISBN 0-8804-8299-0
Selected articles
- Inwang, E. E., Mosnaim, A. D., & Sabelli, H. C. (1973). Isolation and characterization of phenylethylamine and phenylethanolamine from human brain. Journal of Neurochemistry, 20(5), 1469–1473.
- Sabelli, H. C., & MOSNAIM, A. D. (1974). Phenylethylamine hypothesis of affective behavior. American Journal of Psychiatry, 131(6), 695–699.
- Wolf, M. E., & Mosnaim, A. D. (1983). Phenylethylamine in neuropsychiatric disorders. General Pharmacology: The Vascular System, 14(4), 385–390.
- Wolf, M. E., Alavi, A., & Mosnaim, A. D. (1988). Posttraumatic stress disorder in Vietnam veterans—clinical and EEG findings: Possible therapeutic effects of carbamazepine. Biological Psychiatry.
- Mosnaim, A. D., Ranade, V. V., Wolf, M. E., Puente, J., & Valenzuela, M. A. (2006). Phenothiazine molecule provides the basic chemical structure for various classes of pharmacotherapeutic agents. American journal of therapeutics, 13(3), 261–273.
References
- ↑ 1.0 1.1 1.2 "Aron D. Mosnaim, PhD". https://www.rosalindfranklin.edu/academics/faculty/aron-d-mosnaim/.
- ↑ 2.0 2.1 2.2 "walsh medical media | journals | open access journals". November 25, 2019. https://www.walshmedicalmedia.com/.
- ↑ "Noncatecholic phenylethylamines". https://www.worldcat.org/title/3516955.
- ↑ Kinzie, J. David (October 7, 1991). "Posttraumatic stress disorder: Etiology, phenomenology and treatment. By M. E. Wolf, and A. D. Mosnaim, editors. Washington, D.C.: American Psychiatric Press, Inc., 1990, 270 pages". Journal of Traumatic Stress 4 (4): 607–608. doi:10.1002/jts.2490040416. https://onlinelibrary.wiley.com/doi/10.1002/jts.2490040416.
- ↑ "Tardive dyskinesia : biological mechanisms and clinical aspects". https://www.worldcat.org/title/17953812.
- ↑ Mosnaim, A. D.; Wolf, M. E.; Saavedra, I.; Amaro, A. M.; Cordano, G.; Nonhebel, D. C. (January 1, 1973). "Reaction of cupric(ii) halides with organic compounds-VIII pyrene and some 3-substituted pyrenes". Tetrahedron Letters 14 (17): 1491–1494. doi:10.1016/S0040-4039(01)95980-5. https://www.sciencedirect.com/science/article/pii/S0040403901959805.
- ↑ Mosnaim, A. D.; Inwang, E. E.; Sugerman, J. H.; DeMartini, W. J.; Sabelli, H. C. (June 7, 1973). "Ultraviolet spectrophotometric determination of 2-phenylethylamine in biological samples and its possible correlation with depression". Biological Psychiatry 6 (3): 235–257. PMID 4732254. https://pubmed.ncbi.nlm.nih.gov/4732254/.
- ↑ Inwang, E. E.; Mosnaim, A. D.; Sabelli, H. C. (May 7, 1973). "Isolation and characterization of phenylethylamine and phenylethanolamine from human brain". Journal of Neurochemistry 20 (5): 1469–1473. doi:10.1111/j.1471-4159.1973.tb00259.x. PMID 4716838. https://onlinelibrary.wiley.com/doi/10.1111/j.1471-4159.1973.tb00259.x.
- ↑ "Noncatecholic phenylethylamines. Pt. 1 Phenylethylamine: biological mechanisms and clinical aspects ; Mosnaim, Aron D., Wolf, Marion E". https://www.worldcat.org/title/84492628.
- ↑ Wolf, Marion E.; Mosnaim, A. D. (January 1, 1983). "Phenylethylamine in neuropsychiatric disorders". General Pharmacology: The Vascular System 14 (4): 385–390. doi:10.1016/0306-3623(83)90020-4. PMID 6352395. https://dx.doi.org/10.1016/0306-3623%2883%2990020-4.
- ↑ Sabelli, H. C.; Vazquez, A. J.; Mosnaim, A. D.; Madrid-Pedemonte, L. (March 7, 1974). "2-Phenylethylamine as a possible mediator for Δ9-tetrahydrocannabinol-induced stimulation". Nature 248 (5444): 144–145. doi:10.1038/248144a0. PMID 4274244. Bibcode: 1974Natur.248..144S. https://www.nature.com/articles/248144a0.
- ↑ Mosnaim, Aron D.; Callaghan, Owen H.; Hudzik, Thomas; Wolf, Marion E. (April 1, 2013). "Rat Brain-Uptake Index for Phenylethylamine and Various Monomethylated Derivatives". Neurochemical Research 38 (4): 842–846. doi:10.1007/s11064-013-0988-1. PMID 23389662. https://doi.org/10.1007/s11064-013-0988-1.
- ↑ Mosnaim, Aron D.; Wolf, Marion E.; III. O’Donnell, James J.; Hudzik, Thomas (July 3, 2020). "β-Phenylethylamine and various monomethylated and para-halogenated analogs. Acute toxicity studies in mice". Drug and Chemical Toxicology 43 (4): 369–372. doi:10.1080/01480545.2018.1551899. PMID 30614291. https://www.tandfonline.com/doi/full/10.1080/01480545.2018.1551899.
- ↑ Mosnaim, Aron D.; Puente, Javier; Saavedra, Rolando; Diamond, Seymour; Wolf, Marion E. (December 4, 2002). "In vitro Human Plasma Leucine5-Enkephalin Degradation Is Inhibited by a Select Number of Drugs with the Phenothiazine Molecule in Their Chemical Structure". Pharmacology 67 (1): 6–13. doi:10.1159/000066781. PMID 12444298. https://doi.org/10.1159/000066781.
- ↑ Mosnaim, Aron D.; Wolf, Marion E.; Chevesich, Jorge; Callaghan, Owen H.; Diamond, Seymour (July 7, 1985). "Plasma Methionine Enkephalin Levels – A Biological Marker for Migraine?". Headache: The Journal of Head and Face Pain 25 (5): 259–267. doi:10.1111/j.1526-4610.1985.hed2505259.x. PMID 4030316. https://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.1985.hed2505259.x.
- ↑ Mosnaim, Aron D.; Diamond, Seymour; Freitag, Frederick; Chevesich, Jorge; Wolf, Marion E.; Solomon, Glen (June 7, 1987). "Plasma and Platelet Methionine-Enkephalin Levels in Chronic Cluster Patients During an Acute Headache Episode". Headache: The Journal of Head and Face Pain 27 (6): 325–328. doi:10.1111/j.1526-4610.1987.hed2706325.x. PMID 3654188. https://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.1987.hed2706325.x.
- ↑ "Migraine and the contents of tyramine and phenylethylamine in food – Biological Psychiatry". https://www.biologicalpsychiatryjournal.com/article/0006-3223(96)84270-3/pdf.
- ↑ Wolf, M E; Chevesich, J; Lehrer, E; Mosnaim, A D (October 1, 1983). "The clinical association of tardive dyskinesia and drug-induced parkinsonism". Biological Psychiatry 18 (10): 1181–1188. PMID 6140032. https://europepmc.org/article/MED/6140032.
- ↑ Wolf, Marion E.; Mosnaim, Aron D. (August 7, 1984). "Identifying Subtypes of Tardive Dyskinesia". Psychiatric Services 35 (8): 828–830. doi:10.1176/ps.35.8.828. PMID 6479919. http://psychiatryonline.org/doi/abs/10.1176/ps.35.8.828.
- ↑ Wolf, Marion E.; Ryan, Joseph J.; Mosnaim, Aron D. (August 7, 1983). "Cognitive functions in tardive dyskinesia". Psychological Medicine 13 (3): 671–674. doi:10.1017/S0033291700048108. PMID 6137851. https://www.cambridge.org/core/journals/psychological-medicine/article/abs/cognitive-functions-in-tardive-dyskinesia/B66521928E2D20A76EDA9F7ED49C835D.
- ↑ Wolf, M. E.; DeWolfe, A. S.; Ryan, J. J.; Lips, O.; Mosnaim, A. D. (September 1, 1985). "Vulnerability to tardive dyskinesia". The Journal of Clinical Psychiatry 46 (9): 367–368. PMID 2863257. https://europepmc.org/article/MED/2863257.
- ↑ "Pain, dermatological and allergic conditions in post traumatic stress disorder". https://www.researchgate.net/publication/316541249.
- ↑ Maturana, Patricio; Puente, Javier; Miranda, Dante; Sepulveda, Cecilia; Wolf, Marion E.; Mosnaim, Aron D. (March 1, 1991). "Natural killer cell activity in patients with septic shock". Journal of Critical Care 6 (1): 42–45. doi:10.1016/0883-9441(91)90032-O. https://dx.doi.org/10.1016/0883-9441%2891%2990032-O.
- ↑ Sepúlveda, Cecilia; Puente, Javier; Weinstein, Caroline; Wolf, Marion E.; Mosnaim, Aron D. (November 7, 1997). "ENHANCEMENT OF NATURAL KILLER CELL ACTIVITY IN HIV-1-INFECTED SUBJECTS BY A MIXTURE OF THE CALCIUM IONOPHORE A23187 AND THE PHORBOL ESTER TPA: LACK OF RESPONSE TO A SIMILAR CHALLENGE WITH INTERLEUKIN-2 OR α-INTERFERON". American Journal of Therapeutics 4 (11): 413–421. doi:10.1097/00045391-199711000-00013. PMID 10423640. https://journals.lww.com/americantherapeutics/Abstract/1997/11000/ENHANCEMENT_OF_NATURAL_KILLER_CELL_ACTIVITY_IN.13.aspx.
- ↑ Puente, J.; Carvajal, T.; Parra, S.; Miranda, D.; Sepulveda, C.; Wolf, M. E.; Mosnaim, A. D. (June 7, 1993). "In vitro studies of natural killer cell activity in septic shock patients. Response to a challenge with alpha-interferon and interleukin-2". International Journal of Clinical Pharmacology, Therapy, and Toxicology 31 (6): 271–275. PMID 8335423. https://pubmed.ncbi.nlm.nih.gov/8335423/.
Original source: https://en.wikipedia.org/wiki/Aron Mosnaim.
Read more |